OliX is a clinical stage biotechnology company.
OliX is a clinical stage biotechnology company, based on their own proprietary RNA interference (RNAi) technology regulating the expression of disease-causing genes.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 1, 2020 | Post-IPO Equity | ₩41.50B | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Widwin Investment | — | Post-IPO Equity |